JB Chemicals & Pharmaceuticals (JBCPL) has received its shareholder’ for the sale of its over-the-counter business in Russia and CIS countries to Johnson & Johnson subsidiary Cilag GmbH for a consideration of Rs 938 crore.
The shareholders’ approval for the agreement follows the nod given to the pact by the board of directors in May this year.
The Russia/CIS (Commonwealth of Independent States) OTC business is being sold as a going concern on a slump sale basis, including trademarks, brand, patents, registrations and domain names, the company had said in an earlier statement
Recently, the company had launched its new -- Femident Division -- catering to Gynecology and Dental products, in its domestic formulations business. The company has launched this division with over 100 medical representatives and 15 products some of which are first of its kind in its respective segment
JBCPL is one of India’s leading pharmaceutical companies which manufacture and markets a diverse range of pharmaceutical formulations, herbal remedies and APIs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: